Marshall Wace
CRVS icon

Marshall Wace’s Corvus Pharmaceuticals CRVS Stock Holding History

Marshall Wace’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.02M Buy
548,285
+332,037
+154% +$5.3M 0.01% 1078
2025
Q4 		$1.67M Buy
+216,248
New +$1.71M ﹤0.01% 1665
2025
Q3 		– Sell
-201,651
Closed -$807K – 2964
2025
Q2 		$807K Buy
201,651
+46,880
+30% +$171K ﹤0.01% 1941
2025
Q1 		$492K Buy
+154,771
New +$729K ﹤0.01% 2084
2024
Q4 		– Sell
-323,211
Closed -$1.71M – 2642
2024
Q3 		$1.71M Buy
323,211
+248,652
+333% +$893K ﹤0.01% 1430
2024
Q2 		$136K Buy
+74,559
New +$139K ﹤0.01% 2367
2023
Q4 		– Sell
-198,220
Closed -$289K – 2235
2023
Q3 		$289K Sell
198,220
-100,920
-34% -$213K ﹤0.01% 1896
2023
Q2 		$685K Buy
+299,140
New +$621K ﹤0.01% 1870

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return